Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies
CONCLUSION: Cross-reactivity may occur between anti-CMV and anti-EBV IgM antibodies with HLA molecules. Thus, in graft recipients, pathogenic IgMs can also act as de novo anti-HLA antibodies and aggravate the rejection process.PMID:37865308 | DOI:10.1016/j.jim.2023.113577 (Source: Journal of Immunological Methods)
Source: Journal of Immunological Methods - October 21, 2023 Category: Allergy & Immunology Authors: Rasime Derya G üleç Fatma Demet Arslan Berk Özyılmaz Nisel Y ılmaz Sevgi Y ılmaz Hancı Şükran Köse Source Type: research
Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies
CONCLUSION: Cross-reactivity may occur between anti-CMV and anti-EBV IgM antibodies with HLA molecules. Thus, in graft recipients, pathogenic IgMs can also act as de novo anti-HLA antibodies and aggravate the rejection process.PMID:37865308 | DOI:10.1016/j.jim.2023.113577 (Source: Journal of Immunological Methods)
Source: Journal of Immunological Methods - October 21, 2023 Category: Allergy & Immunology Authors: Rasime Derya G üleç Fatma Demet Arslan Berk Özyılmaz Nisel Y ılmaz Sevgi Y ılmaz Hancı Şükran Köse Source Type: research
Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies
CONCLUSION: Cross-reactivity may occur between anti-CMV and anti-EBV IgM antibodies with HLA molecules. Thus, in graft recipients, pathogenic IgMs can also act as de novo anti-HLA antibodies and aggravate the rejection process.PMID:37865308 | DOI:10.1016/j.jim.2023.113577 (Source: Journal of Immunological Methods)
Source: Journal of Immunological Methods - October 21, 2023 Category: Allergy & Immunology Authors: Rasime Derya G üleç Fatma Demet Arslan Berk Özyılmaz Nisel Y ılmaz Sevgi Y ılmaz Hancı Şükran Köse Source Type: research
A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog
J Immunol Methods. 2023 Oct 14;523:113575. doi: 10.1016/j.jim.2023.113575. Online ahead of print.ABSTRACTBiotherapeutics have the potential to trigger undesired immune responses in the patients. For therapeutic proteins, immunogenicity is manifested as anti-drug antibodies (ADA). Because ADA could compromise pharmacokinetics, efficacy, and safety, regulatory agencies require immunogenicity assessment during clinical development. A tiered bioanalytical approach is recommended to monitor clinical immunogenicity, and neutralizing antibodies (NAb) are studied in Tier 4 if the molecule is immunogenic. Although cell-based assays...
Source: Journal of Immunological Methods - October 16, 2023 Category: Allergy & Immunology Authors: Victoria L Peek Deven M Lemen Robert J Konrad Yi Wen Source Type: research
A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog
J Immunol Methods. 2023 Oct 14;523:113575. doi: 10.1016/j.jim.2023.113575. Online ahead of print.ABSTRACTBiotherapeutics have the potential to trigger undesired immune responses in the patients. For therapeutic proteins, immunogenicity is manifested as anti-drug antibodies (ADA). Because ADA could compromise pharmacokinetics, efficacy, and safety, regulatory agencies require immunogenicity assessment during clinical development. A tiered bioanalytical approach is recommended to monitor clinical immunogenicity, and neutralizing antibodies (NAb) are studied in Tier 4 if the molecule is immunogenic. Although cell-based assays...
Source: Journal of Immunological Methods - October 16, 2023 Category: Allergy & Immunology Authors: Victoria L Peek Deven M Lemen Robert J Konrad Yi Wen Source Type: research
A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog
J Immunol Methods. 2023 Oct 14;523:113575. doi: 10.1016/j.jim.2023.113575. Online ahead of print.ABSTRACTBiotherapeutics have the potential to trigger undesired immune responses in the patients. For therapeutic proteins, immunogenicity is manifested as anti-drug antibodies (ADA). Because ADA could compromise pharmacokinetics, efficacy, and safety, regulatory agencies require immunogenicity assessment during clinical development. A tiered bioanalytical approach is recommended to monitor clinical immunogenicity, and neutralizing antibodies (NAb) are studied in Tier 4 if the molecule is immunogenic. Although cell-based assays...
Source: Journal of Immunological Methods - October 16, 2023 Category: Allergy & Immunology Authors: Victoria L Peek Deven M Lemen Robert J Konrad Yi Wen Source Type: research
A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog
J Immunol Methods. 2023 Oct 14:113575. doi: 10.1016/j.jim.2023.113575. Online ahead of print.ABSTRACTBiotherapeutics have the potential to trigger undesired immune responses in the patients. For therapeutic proteins, immunogenicity is manifested as anti-drug antibodies (ADA). Because ADA could compromise pharmacokinetics, efficacy, and safety, regulatory agencies require immunogenicity assessment during clinical development. A tiered bioanalytical approach is recommended to monitor clinical immunogenicity, and neutralizing antibodies (NAb) are studied in Tier 4 if the molecule is immunogenic. Although cell-based assays, wh...
Source: Journal of Immunological Methods - October 16, 2023 Category: Allergy & Immunology Authors: Victoria L Peek Deven M Lemen Robert J Konrad Yi Wen Source Type: research
A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog
J Immunol Methods. 2023 Oct 14:113575. doi: 10.1016/j.jim.2023.113575. Online ahead of print.ABSTRACTBiotherapeutics have the potential to trigger undesired immune responses in the patients. For therapeutic proteins, immunogenicity is manifested as anti-drug antibodies (ADA). Because ADA could compromise pharmacokinetics, efficacy, and safety, regulatory agencies require immunogenicity assessment during clinical development. A tiered bioanalytical approach is recommended to monitor clinical immunogenicity, and neutralizing antibodies (NAb) are studied in Tier 4 if the molecule is immunogenic. Although cell-based assays, wh...
Source: Journal of Immunological Methods - October 16, 2023 Category: Allergy & Immunology Authors: Victoria L Peek Deven M Lemen Robert J Konrad Yi Wen Source Type: research
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfa
J Immunol Methods. 2023 Oct 9;522:113573. doi: 10.1016/j.jim.2023.113573. Online ahead of print.ABSTRACTZinpentraxin alfa (rhPTX-2; PRM-151) is currently being developed for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and myelofibrosis. Notably, because it is administered chronically and has an endogenously expressed counterpart, clinical studies of zinpentraxin alpha must include immunogenicity assessments. Since the typical homogenous bridging ELISA assay does not adequately measure anti-drug antibodies (ADAs) against zinpentraxin alfa, additional assay formats have been developed to evaluate...
Source: Journal of Immunological Methods - October 10, 2023 Category: Allergy & Immunology Authors: Xiaoyun Yang Ketevan Siradze Gizette Sperinde Audrey Arjomandi Saloumeh Fischer Source Type: research
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfa
J Immunol Methods. 2023 Oct 9;522:113573. doi: 10.1016/j.jim.2023.113573. Online ahead of print.ABSTRACTZinpentraxin alfa (rhPTX-2; PRM-151) is currently being developed for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and myelofibrosis. Notably, because it is administered chronically and has an endogenously expressed counterpart, clinical studies of zinpentraxin alpha must include immunogenicity assessments. Since the typical homogenous bridging ELISA assay does not adequately measure anti-drug antibodies (ADAs) against zinpentraxin alfa, additional assay formats have been developed to evaluate...
Source: Journal of Immunological Methods - October 10, 2023 Category: Allergy & Immunology Authors: Xiaoyun Yang Ketevan Siradze Gizette Sperinde Audrey Arjomandi Saloumeh Fischer Source Type: research
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfa
J Immunol Methods. 2023 Oct 8:113573. doi: 10.1016/j.jim.2023.113573. Online ahead of print.ABSTRACTZinpentraxin alfa (rhPTX-2; PRM-151) is currently being developed for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and myelofibrosis. Notably, because it is administered chronically and has an endogenously expressed counterpart, clinical studies of zinpentraxin alpha must include immunogenicity assessments. Since the typical homogenous bridging ELISA assay does not adequately measure anti-drug antibodies (ADAs) against zinpentraxin alfa, additional assay formats have been developed to evaluate imm...
Source: Journal of Immunological Methods - October 10, 2023 Category: Allergy & Immunology Authors: Xiaoyun Yang Ketevan Siradze Gizette Sperinde Audrey Arjomandi Saloumeh Fischer Source Type: research
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfa
J Immunol Methods. 2023 Oct 8:113573. doi: 10.1016/j.jim.2023.113573. Online ahead of print.ABSTRACTZinpentraxin alfa (rhPTX-2; PRM-151) is currently being developed for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and myelofibrosis. Notably, because it is administered chronically and has an endogenously expressed counterpart, clinical studies of zinpentraxin alpha must include immunogenicity assessments. Since the typical homogenous bridging ELISA assay does not adequately measure anti-drug antibodies (ADAs) against zinpentraxin alfa, additional assay formats have been developed to evaluate imm...
Source: Journal of Immunological Methods - October 10, 2023 Category: Allergy & Immunology Authors: Xiaoyun Yang Ketevan Siradze Gizette Sperinde Audrey Arjomandi Saloumeh Fischer Source Type: research
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfa
J Immunol Methods. 2023 Oct 8:113573. doi: 10.1016/j.jim.2023.113573. Online ahead of print.ABSTRACTZinpentraxin alfa (rhPTX-2; PRM-151) is currently being developed for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and myelofibrosis. Notably, because it is administered chronically and has an endogenously expressed counterpart, clinical studies of zinpentraxin alpha must include immunogenicity assessments. Since the typical homogenous bridging ELISA assay does not adequately measure anti-drug antibodies (ADAs) against zinpentraxin alfa, additional assay formats have been developed to evaluate imm...
Source: Journal of Immunological Methods - October 10, 2023 Category: Allergy & Immunology Authors: Xiaoyun Yang Ketevan Siradze Gizette Sperinde Audrey Arjomandi Saloumeh Fischer Source Type: research
Impact of bridge heterology on functional parameters of ELISA for 17 α-methyltestosterone
In this study, we have developed bridge heterologous ELISA for the detection of 17α- Methyltestosterone by incorporating aromatic spacers between 17α-Methyltestosterone-3-Carboxymethyloxime and Horseradish peroxidase label through N-hydroxysuccinimide mediated carbodiimide reaction method. The immunogen 17α-Methyltestosterone-3-Carboxymethyloxime-Bovine serum albumin used to generate the antibody was also prepared by the N-hydroxysuccinimide mediated carbodiimide reaction without using any spacer. We have studied the impact of bridge/aromatic spacers on functional parameters i.e. sensitivity, affinity and ED50 of the br...
Source: Journal of Immunological Methods - September 29, 2023 Category: Allergy & Immunology Authors: Divya Verma T G Shrivastav Sonu Chand Thakur Source Type: research
Diagnosis of septic shock by serum measurement of human neutrophil lipocalin by a rapid homogeneous assay
CONCLUSIONS: As an assessment tool, we found that our AlphaLISA had good consistency with an ELISA and had several other advantages, including requiring a shorter processing time and detecting a wider range of serum HNL concentrations. Monitoring serum HNL levels of patients admitted to the ICU might be useful in distinguishing sepsis patients who have septic shock from other sepsis patients, indicating its value in the prediction of sepsis patient prognosis.PMID:37774777 | DOI:10.1016/j.jim.2023.113570 (Source: Journal of Immunological Methods)
Source: Journal of Immunological Methods - September 29, 2023 Category: Allergy & Immunology Authors: Huijun Zong Xueyi Shang Xin Wang Ting Chen Ye Wang Yuhao Ren Yongqiang Jiang Yan Li Qingyu Lv Peng Liu Source Type: research
